Marking One Year Milestone, ADDI Expands Access to Global Data for Alzheimer's Researchers
PR93102
SEATTLE, Nov. 17, 2021 /PRNewswire=KYODO JBN/ --
-- Organization saw growth in AD Workbench users, data partners, and patient
datasets from across the globe, including from low- and middle-income
countries
Today, the Alzheimer's Disease Data Initiative (ADDI) marked one year of
transforming how Alzheimer's disease and related dementias will be treated by
significantly increasing access to data from academic institutions,
government-sponsored organizations, pharmaceutical companies, and others
dedicated to data sharing and collaboration.
Logo - https://mma.prnewswire.com/media/1335810/ADDI_Logo.jpg
"One year ago, ADDI took our first steps on the path to tackling the hard
problems of data access in Alzheimer's research in close collaboration with
partners who share our vision," said Executive Director Tetsuyuki Maruyama. "We
started by dedicating the resources needed to build a platform that breaks down
barriers so that the research community can access, analyze, store and share
the data needed to accelerate progress on treating and curing Alzheimer's
disease. The progress ADDI and our partners have made in such a short amount of
time is inspiring."
Since its launch last year, ADDI's cloud-based Alzheimer's Disease (AD)
Workbench has built a community of over 2,000 users in 80 countries, who have
created more than 200 workspaces with access to over 35 datasets, many of which
include data from diverse populations around the world. Researchers can also
bring their own data into a secure workspace to analyze and make connections
across multiple datasets. The trove of data available on the AD Workbench at no
cost to registered users includes observational clinical trials, synthetic
cohort studies, and synthetic brain images, all accessible in a secure and
centralized location that allows researchers to explore freely field-level
metadata and investigate datasets.
In addition to these milestones, ADDI also celebrated the following
achievements:
- The first European data partner, the European Prevention of Alzheimer's
Dementia (EPAD) Consortium, which includes their first academic partner
– the University of Edinburgh.
- The first major industry partnership with Eli Lilly and Company (Lilly),
which shared their GERAS-EU study dataset. This was later followed by
three other GERAS studies that now include data from seven countries
(France, Germany, Italy, Japan, Spain, the United Kingdom, and the
United States).
- Access to 19 new datasets from Lilly and GlaxoSmithKline (GSK) through
a partnership with Vivli and interoperability with the Vivli platform.
- The first data sharing partner in Asia, the Indian Institute of Science
Centre for Brain Research, which will provide federated access through
the AD Workbench to home visit data.
"The success of our Data Science Challenge substantially increased user
engagement on our platform and the introduction of data sharing capability in a
federated manner effectively addressed data contributors' requirement to be
able to share data securely and remotely," said Mukta Phatak, Director of Data
Science at ADDI. "The AD Workbench will continue to expand and evolve with the
addition of new datasets, analysis tools, and other products and services to
meet the needs of the research community who are working to find treatments and
cures for this disease."
ADDI is currently in the process of adding more than 15 additional datasets in
the next year. They also plan to expand their data sharing community into a
gateway where researchers, data providers, and the broader Alzheimer's and
related dementia community can come together to share ideas, post questions,
and offer tools or resources that further efforts to find answers to shared
challenges.
For more information please visit: www.Alzheimersdata.org
Alzheimer's Disease Data Initiative (ADDI), a 501 (c)(3) medical research
organization (MRO) in partnership with the University of Washington, is
dedicated to advancing scientific breakthroughs in the treatment of Alzheimer's
disease and related dementias. ADDI aims to increase interoperability of
existing data platforms globally, increase sharing of dementia-related data
from academic and industry sources, and empower scientists to find, search,
combine, and analyze data that could lead to new discoveries in dementia
research. ADDI also aims to enhance or fill gaps in datasets, including
enabling the generation of more demographically representative datasets.
LinkedIn: AlzheimersData (
) Twitter: AlzData (
)
SOURCE: Alzheimer’s Disease Data Initiative (ADDI)
CONTACT: Eric Conrad, +1 (202) 813-4815 | eric.conrad@gmmb.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。